Navigation Links
Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Date:9/13/2007

e connect to Arena's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... for Tuesday, December 9 at 11:00 am ET to Discuss ... , SOUTH SAN FRANCISCO, Calif., Dec. ... SNSS ), a biopharmaceutical company focused on the development and ... its studies of voreloxin in acute myeloid leukemia (AML) will ...
... 1 Vical Incorporated (Nasdaq: VICL ) announced ... Merck & Co., Inc. based on Merck,s planned initiation of ... (pDNA) cancer vaccine. The candidate vaccine is based on Vical,s ... (hTERT). hTERT is the subject of separate license agreement. , ...
Cached Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:7/9/2014)... Chase Cancer Center paint a relatively optimistic picture of ... that have spread to the chest wall or skin, ... the skin, regardless of size and whether they have ... and called "locally advanced" tumors, suggesting that they ... poor survival. Locally advanced breast cancers of this and ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... is one of the most important organs in the ... utilize our food properly this is its synthesis ... our organism this is its detoxification function. Lack ... food all damage the liver. The resulting diseased cells ... and life-threatening liver failure. According to the German Liver ...
Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... always been stated time and again that smoking is injurious ... respiratory system. The effects of smoking may be understood by ... // lungs., ,Monoamine oxidase A (MAOA) is important in ... blood pressure. In a new study, researchers at the National ...
... disease which afflicts hundreds of elderly people may be a ... keep patients mentally agile and slow the crippling illness, say ... and not a normal process of ageing with phases of ... is past, the person slowly goes blank," N.M. Narula, president ...
... cancer is the most common cancer affecting men and occurs ... Men above the age of 50 years should undergo the ... // Prostate Specific Antigen, by monitoring the levels of PSA ... of the disease should begin regular prostate screening exams at ...
... published in the new issue of Archives of Facial ... with treatment procedures like laser therapy and other procedures. ... form an external birthmark and can be disfiguring, especially ... had presented the current treatment approaches for port-wine stains ...
... characterized by distorted, sickle shaped red blood cells. The disease ... the kidneys, spleen, and liver. The sickle cell disease is ... 1 in 500., ,Despite much clinical work, there is ... relieved, and the frequency and duration of the crises can ...
... San Francisco have found that eating five or more ... of pancreatic cancer by 50 per cent. ... were onions, garlic, beans, yellow vegetables (such as carrots, ... vegetables and cruciferous vegetables. Light-green vegetables, tomatoes and tomato ...
Cached Medicine News:Health News:Active Lifestyle Helps To Slowdown Illness In Alzheimer's Patients 2Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2
... The Sidekick Testing System is the smallest ... System is there when you need it ... or suitcase, or simply in your purse or ... take wherever you go. And, because it's so ...
Inquire...
Inquire...
... Tube is a cost-effective method of providing ... your patient. The warming tube is ideal ... Cath. Lab., and Radiology. The CSZ Warming ... warm patients since it may be used ...
Medicine Products: